UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.)¹

T2 Biosystems, Inc. (Name of Issuer)

Common Stock, par value \$0.001 per share (Title of Class of Securities)

89853L302

(CUSIP Number)

October 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 \square Rule 13d-1(b)

 \boxtimes Rule 13d-1(c)

 \Box Rule 13d-1(d)

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

	-		
1	NAME OF REPO	DRTING PERSON	
	JACOB SA		
2	CHECK THE AP	(a) 🗆	
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
NUMBER OF	UNITED S		
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		1 000 000	
OWNED BY	6	1,000,000 SHARED VOTING POWER	
EACH	0	SHARED VOTING FOWER	
REPORTING		-0-	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	,		
		1,000,000	
	8	SHARED DISPOSITIVE POWER	
		-0-	
9	AGGREGATE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,000,000		
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	5.7%		
12	5.7% TYPE OF REPOI	PTING DEDSON	
12	I I FE OF KEPOI		
	IN		
<u> </u>			

CUSIP No. 89853L302

1	NAME OF REPORTING PERSON			
-		DINGS, LLC		
2	CHECK THE AP	PROPRIATE BOX IF A MEMBER OF A GROUP	$(a) \square$	
			(b) 🗆	
3	SEC USE ONLY			
5	SEC USE ONEI			
4	CITIZENSHIP O	CITIZENSHIP OR PLACE OF ORGANIZATION		
	DELAWAR			
NUMBER OF	5	SOLE VOTING POWER		
SHARES BENEFICIALLY		1,000,000		
OWNED BY	6	1,000,000 SHARED VOTING POWER		
EACH	0	SHARED VOTINO FOWER		
REPORTING		-0-		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		1,000,000		
	8	SHARED DISPOSITIVE POWER		
		-0-		
9	AGGREGATE AL	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
)	AGOREGALE A	WOUNT BENEFICIALET OWNED DT EACH NEI OKTING TEKSON		
	1,000,000			
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CI	LASS REPRESENTED BY AMOUNT IN ROW (9)		
	5.7%			
12	5.7% TYPE OF REPOR	RTING PERSON		
12	I I FE OF KEPOF			
	00			

CUSIP No. 89853L302			
Item 1(a).	Name of Issuer:		
	T2 Biosystems, Inc. (the "Issuer").		
Item 1(b).	Address of Issuer's Principal Executive Offices:		
	101 Hartwell Ave. Lexington, MA 02421		
Item 2(a). Item 2(b). Item 2(c).	Name of Person Filing: Address of Principal Business Office or, if None, Residence: Citizenship:		
	JSAF Holdings, LLC ("JSAF") c/o The Wolfson Group One State Street Plaza, 29 th Floor New York, NY 10004 Citizenship: United States		
	Jacob Safier c/o The Wolfson Group One State Street Plaza, 29 th Floor New York, NY 10004 Citizenship: United States		
	Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."		
Item 2(d).	Title of Class of Securities:		
	Common Stock, par value \$0.001 per share (the "Shares").		
Item 2(e).	CUSIP Number:		
	89853L302		

Item 3.	Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:				
		/x/	Not applicable.		
	(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.		
	(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.		
	(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.		
	(d)	//	Investment company registered under Section 8 of the Investment Company Act.		
	(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).		
	(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).		
	(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).		
	(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.		
	(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.		
	(j)	//	Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).		
	(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:		

Item 4. Ownership.

(a) Amount beneficially owned:

As of the date hereof:

JSAF beneficially owns 1,000,000 Shares.

Jacob Safier, as the portfolio manager of the T2 Biosystems, Inc. investment by JSAF, may be deemed to beneficially own the Shares owned by JSAF and, therefore, may be deemed to beneficially own 1,000,000 Shares.

(b) Percent of class:

As of the date hereof, JSAF beneficially owned and Jacob Safier may be deemed to beneficially own 5.7% (based upon 17,479,954 Shares outstanding, which is the number of Shares reported as outstanding in the Issuer's Quarterly Statement on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024).

CUSIP No. 89853L302

0001110						
(c)	Numb	per of shares as to which such person has:				
	(i)	Sole power to vote or to direct the vote:				
		1,000,000 Shares.				
	(ii)	Shared power to vote or to direct the vote:				
		0 Shares.				
	(iii)	Sole power to dispose or to direct the disposition of:				
		1,000,000 Shares				
	(iv)	Shared power to dispose or to direct the disposition of:				
		0 Shares.				
Item 5.	Owne	Ownership of Five Percent or Less of a Class.				
	Not A	pplicable.				
Item 6.	Owne	Ownership of More than Five Percent on Behalf of Another Person.				
	Not A	pplicable.				
Item 7.		fication and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding any or Control Person.				
	Not A	Not Applicable.				
Item 8.	Identi	Identification and Classification of Members of the Group.				
	Not A	pplicable.				
Item 9.	Notice	e of Dissolution of Group.				
	Not A	pplicable.				
Item 10.	Certif	ications.				
	By sig	By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not				

acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his or her knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: November 6, 2024

JSAF Holdings, LLC

By: /s/ Jacob Safier

Name: Jacob Safier Title: Manager

/s/ Jacob Safier

Jacob Safier

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated November 6, 2024 with respect to the Common Stock, par value 0.001 per share, of T2 Biosystems, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: November 6, 2024

JSAF Holdings, LLC

By: /s/ Jacob Safier

Name:Jacob SafierTitle:Manager

/s/ Jacob Safier Jacob Safier